? COMPARATIVE PATHOLOGY & DIGITAL IMAGING SHARED RESOURCE (CPDISR) The CPDISR provides expert, readily available and affordable experimental pathology support to investigators conducting research for understanding the development and treatment of cancer using preclinical animal models and/or human tissues procured for translational research. During the current funding period, a recent major development was the inclusion of complete histology services optimized for human tissues, as well as expanded slide digitization and quantitative image analysis services for stained human and animal tissue slides. As a result, Dr. Anil Parwani (MCC) has been named co-Director with Dr. Krista La Perle (CB), the name of the shared resource (SR) has been changed to the Comparative Pathology & Digital Imaging Shared Resource, and the Specific Aims have been modified accordingly.
The Specific Aims are to: 1) provide consultative services to OSUCCC investigators for optimal experimental design, sample submission and data analysis, and interactions with other SRs; 2) provide support for preclinical efficacy and toxicity animal studies as well as translational studies that utilize human tissues; and 3) perform digitization and quantitative image analysis of stained slides from animal and human tissues. During the current 5-year grant cycle, a third board certified veterinary pathologist and seven additional technical staff have been added to anticipate usage in conjunction with the robust OSUCCC recruitment and strategic priorities. The CPDISR also acquired a Leica PELORIS 3 dual retort tissue processor after successful peer-reviewed funding through the OSUCCC Intramural Research Program. During this grant cycle, the CPDISR contributed to 84 publications (12 > 10 impact factor), 537 investigators, and 57 NCI grants, including 1 K12, 1 K22, 1 K24, 5 P01s, 1 P50, 35 R01s, 7 R21s, 2 R35s, 1 T32, and 3 U01s involving members of all five OSUCCC research programs. For the next grant cycle, the CPDISR will be a regular member of the Immune Monitoring and Discovery Platform, an overarching shared resource initiative fostering complex immuno-oncology projects. In addition, a major emphasis will be to continue to expand our available menu of antibodies optimized for immunohistochemistry, immunofluorescence and in situ hybridization in tissues of animal and human origin by various staining platforms, including multiplexing, according to the specific needs of OSUCCC members. We will also increase our support of image analysis projects allowing machine learning approaches to be developed with the center for cancer engineering; and continue to evaluate available open source and commercial image analysis software platforms/modules to complement our Aperio and Visiopharm software in order to quantify biomarkers in animal and human tissues. The annual budget of the CPDISR is $1,863,254, yet the CCSG request is $107,366. As such, the CPDIR seeks only 5.8% budgetary support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090009
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Moshiri, Jasmine; Kaur, Darpan; Hambira, Chido M et al. (2018) Identification of a Small Molecule Anti-biofilm Agent Against Salmonella enterica. Front Microbiol 9:2804
Serna, Vanida A; Wu, Xin; Qiang, Wenan et al. (2018) Cellular kinetics of MED12-mutant uterine leiomyoma growth and regression in vivo. Endocr Relat Cancer 25:747-759
Dabrowski, Konrad; Miller, Mackenzie (2018) Contested Paradigm in Raising Zebrafish (Danio rerio). Zebrafish 15:295-309
Krok-Schoen, Jessica L; Fisher, James L; Baltic, Ryan D et al. (2018) White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival Among Older Adults. J Aging Health 30:863-881
Killian, Jackson A; Topiwala, Taha M; Pelletier, Alex R et al. (2018) FuSpot: a web-based tool for visual evaluation of fusion candidates. BMC Genomics 19:139
Sizemore, Gina M; Balakrishnan, Subhasree; Thies, Katie A et al. (2018) Stromal PTEN determines mammary epithelial response to radiotherapy. Nat Commun 9:2783
Zeng, Rong; Liu, Yi; Jiang, Zhao-Jing et al. (2018) EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int J Oncol :
Kotlarek, Marta; Kubiak, Anna; Czetwerty?ska, Ma?gorzata et al. (2018) The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma. Int J Mol Sci 19:
Li, Feng; Malli, Ahmad; Cruz-Monserrate, Zobeida et al. (2018) Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts. World J Gastrointest Endosc 10:1-9
He, Huiling; Li, Wei; Yan, Pearlly et al. (2018) Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. Thyroid 28:748-754

Showing the most recent 10 out of 2602 publications